drugset / Trial / NCT05328102
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in participants with relapsed or refractory DLBCL.
Timeline
- Start
- 2022-04-15
- Primary completion
- 2023-02-21
- Completion
- 2023-02-21
Outcome
Outcome not reported
Stopped (Business): “The study has been terminated early by the sponsor due to business decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plamotamab | Monoclonal antibody | — | — |
| Background | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Background | Tafasitamab | Monoclonal antibody | 12 mg/kg | Intravenous |